OPKO Health, Inc. (NASDAQ:OPK) will present abstracts at the 55th Annual Meeting of the European Society for Paediatric Endocrinology (ESPE) to be held …
Opko Health Inc. (NASDAQ:OPK) announces that it has completed its previously announced acquisition of Transition Therapeutics, Inc.
Opko Health Inc. (NASDAQ:OPK) announces that at a Special Shareholder Meeting held on August 25, 2016, shareholders of Transition Therapeutics, Inc.
Opko Health Inc. (NASDAQ:OPK) is aware of a press release by Purcell Julie & Lefkowitz, LLP, a class action litigation firm, that it …
Oppenheimer analyst Rohit Vanjani came out today with a neutral stance on shares of Opko Health Inc. (NASDAQ:OPK), after the drug maker reported second-quarter results, posting revenue …
Opko Health Inc. (NASDAQ:OPK) reports financial and operating results for the three and six months ended June 30, 2016.
Opko Health Inc. (NASDAQ:OPK) announce the signing of a definitive agreement under which OPKO will acquire Transition Therapeutics, a clinical stage biotechnology company.
Analysts maintain bullish stances on biotech companies Opko Health Inc. (NYSE:OPK) and Ariad Pharmaceuticals, Inc.
On Wednesday, Opko Health Inc. (NYSE:OPK) hosted an Analyst & Investor Day providing an overview of its diversified business units and update on continued progress …
Opko Health Inc. (NYSE:OPK) announces that it will move its stock exchange listing to The NASDAQ Stock Market from The New York Stock Exchange.
